Inhibiting Serotonin Synthesis for the Treatment of Pulmonary Arterial Hypertension
Authors:
Open Access
- 1 April 2025
- journal article
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (2) , e70100
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Inhalation of the Novel Tryptophan Hydroxylase 1 Inhibitor TPT-004 Alleviates Pulmonary Arterial HypertensionAmerican Journal of Respiratory Cell and Molecular Biology, 2025
- Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trialThe Lancet Respiratory Medicine, 2024
- Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene ExpressionJACC: Basic To Translational Science, 2024
- TPT‐004, a Next‐Generation Inhibitor of Tryptophan Hydroxylase, Ameliorates Pulmonary Arterial Hypertension in RatsJournal of the American Heart Association, 2024
- Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary HypertensionThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cureAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Effect of Tryptophan Hydroxylase 1 Deficiency on the Development of Hypoxia-Induced Pulmonary HypertensionHypertension, 2007